WEDNESDAY, Feb. 29 (HealthDay News) -- A drug that's typically used to treat the flu and Parkinson's disease appears to speed recovery in traumatic brain injury patients, a new study indicates.
Latest Neurology News
Traumatic brain injury (TBI) victims who weren't fully conscious and were discharged to rehabilitation facilities after hospitalization were given amantadine hydrochloride. The drug is already given "off-label" to such patients, but if and how much it helps has remained unclear.
While taking the drug, the patients given amantadine scored better on behavioral tests that measure how well the brain is functioning compared to a group of patients given a placebo, researchers report in the March 1 issue of The New England Journal of Medicine.
"Amantadine appeared to increase the rate of recovery compared to placebo. Patients got better faster while they were on the drug," said study co-author Joseph Giacino, director of rehabilitation neuropsychology at the Spaulding Rehabilitation Hospital, in Boston, and an associate professor in the department of physical medicine and rehabilitation at Harvard Medical School.
Study co-author Dr. John Whyte, director of the Moss Rehabilitation Research Institute at Albert Einstein Healthcare Network, in the Philadelphia area, said previous observational studies had suggested amantadine improved the rate of recovery. While the medicine is already commonly prescribed off-label to treat people suffering from prolonged disorders of consciousness, he said this is the first placebo-controlled trial of the drug in patients who were either in a vegetative state (wakeful but not aware) or a minimally conscious state (able to track with their eyes).
"There were many hypotheses out there about what this drug should do, but there was very little data to support or refute those hypotheses," Whyte explained.
For the study, 184 patients from 11 medical centers in three countries were enrolled. They had all suffered a TBI within the previous one to four months. Half received amantadine while the other half were given a placebo for the first four weeks of the six-week study. Both groups were followed up for two additional weeks, Whyte said.
The researchers used the Disability Rating Scale (DRS) to monitor patients' progress during the treatment and follow-up period. The test measures eye opening, verbal ability and motor response, among other functions, Giacino said.
"During the four-week treatment period, recovery was significantly faster in the amantadine group than the placebo group," said Giacino.
Whyte said during his 25-year career as a brain trauma rehabilitation physician there have been no groundbreaking treatments for these patients. TBI rehabilitation can take months, or years, and many patients do not have the health insurance or private funds to access good rehabilitative care, so a drug that could speed recovery would be a boon, he said.
The ability of patients in a vegetative state or those in the MCS "to access rehab has gotten less and less," Whyte said. "Many of these patients go straight to a nursing home or home with family." He noted that TBI remains the most common cause of death and disability in people between the ages of 15 and 30.
The new finding "is very exciting because we have a new tool to help improve these patients in their early outcome," said one expert, Dr. J. Javier Provencio, director of the Neurocritical Care Fellowship Program at the Cerebrovascular Center of the Cleveland Clinic Neurological Institute.
"The take-home message is that this medicine is promising for patients in a very certain setting. I think the results have to be taken very strictly and not extrapolated to other conditions," said Provencio.
He noted that the rate of improvement in the drug group slowed in weeks five and six. By the study's end, the overall improvement from baseline between the placebo group and the amantadine group was identical.
That means that, "it is still unclear whether the effects last," Provencio said. "In the study, by week six, the effect difference was getting smaller. I hope they follow these patients out to a year to see how they do."
Co-author Giacino said the researchers were surprised when they saw an immediate leveling off between the two groups in the final two weeks.
"But when I take a step back, it is even stronger evidence that this drug was doing something," he added.
Neurologist Dr. Daniel Labovitz, of Montefiore Medical Center in New York City, believes hope should remain in check despite the promising results. "It's not a home run. It's a small change and it was temporary, and I think that would be the message that has to come through."
Labovitz said the drug appears to be gently waking the patients. "If this trial holds up in larger, longer-term studies, maybe you can enhance the ability of [rehabilitation] therapists to interact with patients while they're on the drug."
Giacino said they researchers also aimed to look at side effects of amantadine.
"There was not a single category where the amantadine group had a higher rate of side effects than the placebo group," he said.
Whyte said that while this research may influence more rehabilitation experts to use amantadine for this type of patient, more challenges remain before the drug's impact is completely understood.
"This study isn't the end of the story," Whyte said.
Copyright © 2012 HealthDay. All rights reserved.
SOURCES: Joseph Giacino, Ph.D., director, rehabilitation neuropsychology, Spaulding Rehabilitation Hospital, Boston, and associate professor, department of physical medicine and rehabilitation, Harvard Medical School; John Whyte, M.D., Ph.D., director, Moss Rehabilitation Research Institute, Albert Einstein Healthcare Network, and Brain Injury Program, Bryn Mawr Rehab Hospital, Philadelphia; J. Javier Provencio, MD, director, Neurocritical Care Fellowship Program, Cerebrovascular Center, Cleveland Clinic Neurological Institute; Daniel Labovitz, MD, neurologist, Montefiore Medical Center, New York City; March 1, 2012, New England Journal of Medicine